Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.67 |
| ▸ | LIPE | Q05469 | 1/20 | 0.66 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956447 | 1.00 | ENPP2 (0.67) | ENPP2LIPEPTGER1HTR2CHTR2B | |
| SCHEMBL5110136 | 0.88 | ENPP2 (0.67) | ENPP2LIPEPTGER1HTR2CHTR2B | |
| SCHEMBL4720905 | 0.85 | ENPP2 (0.56) | ENPP2LIPEPTGER1SLC6A4MRGPRX4 | |
| SCHEMBL5103313 | 0.84 | PTGER1 (0.63) | ENPP2LIPEPTGER1CYP2C9 | |
| SCHEMBL28606699 | 0.83 | LIPE (0.68) | ENPP2LIPE | |
| SCHEMBL1753346 | 0.83 | LIPE (0.68) | ENPP2LIPEPTGER1MRGPRX4CYP2C9 | |
| SCHEMBL5109980 | 0.81 | LIPE (0.66) | ENPP2LIPEPTGER1SLC6A4 | |
| SCHEMBL1956146 | 0.81 | LIPE (0.71) | ENPP2LIPEPTGER1MRGPRX4 | |
| SCHEMBL29825616 | 0.81 | LIPE (0.71) | ENPP2LIPEPTGER1MRGPRX4 | |
| SCHEMBL2557075 | 0.81 | LIPE (0.75) | ENPP2LIPECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079829-B | 1,2, 4-triazole [4,3-a ] pyridine derivative and preparation method and application thereof | 四川大学 | 2021-11-26 | — | — | CN | disclosed |
| CN-112079829-A | 1,2, 4-triazole [4,3-a ] pyridine derivative and preparation method and application thereof | 四川大学 | 2020-12-15 | — | — | CN | disclosed |
| US-8722741-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| US-8415394-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8394986-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (GB) | 2013-03-12 | — | — | US | disclosed |
| US-8349897-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2013-01-08 | — | — | US | disclosed |
| EP-1784388-B3 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| US-8163727-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
| CN-1659131-A | (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LTD (GB) | 2005-08-24 | — | — | CN | disclosed |
| EP-1556330-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037794-A1 | CYCLOHEXENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037786-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005018529-A2 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
| EP-1492757-A1 | (2-((2-ALKOXY)-PHENYL)-CYCLOPENT-1-ENYL) AROMATIC CARBO- AND HETEROCYCLIC CARBOXYLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004039753-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003084917-A1 | (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178732-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | CYP26A1, CYP1A1, GPBAR1 | ENPP2 459/4885LIPE 1046/4885PTGER1 403/4885 |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | CYP2C9, CYP2C19, CNR1 | ENPP2 1174/4885LIPE 3274/4885PTGER1 323/4885 |
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | ENPP2 144/4885LIPE 975/4885PTGER1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.